Incretin therapy in cardiometabolic care: Glucose, weight and organ protection

Incretin-based therapies are reshaping the management of type 2 diabetes and obesity. Once regarded primarily as glucose-lowering medicines, glucagon-like peptide-1 receptor agonists and newer dual-agonist therapies now offer substantial weight reduction and, in selected populati...

By Specialist Forum, Endocrinology · 1 Sep 2026